Cure My Disease

Don't miss your cure!

 Log in / Sign up

Step toward prevention: app-based exercise may protect the brain in Parkinson's risk group

NCT ID NCT07324330

Prevention Sponsor: University Hospital, Bonn Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether increasing physical activity through a motivational smartphone app can slow cognitive decline in people with isolated REM sleep behavior disorder (iRBD), an early sign of Parkinson's disease and related disorders. Researchers will enroll 130 participants (80 with iRBD and 50 healthy controls) and track changes in thinking skills, brain imaging, and blood markers over one year. The app encourages users to gradually increase their daily steps and activity intensity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
motivational smartphone application (Alpha-Fit app) to increase physical activity
What this could lead to
If it works, this could point toward a simple, non-drug way to preserve thinking skills in people at high risk for Parkinson's or related diseases.
What could go wrong
This is a relatively small, early-stage study (130 participants) testing a behavioral intervention, so results may not be conclusive or widely applicable. The app-based approach also depends on participants' long-term motivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: iRBD: * Age: 50-80 years * Polysomnographically confirmed diagnosis of iRBD * Maximum of 120 minutes of sports/outdoor activities per day * Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase * Basic smartphone skills * Sufficient knowledge of German (native language, C1 or C2) * Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer) * Consent to be informed of any additional findings Healthy controls: * Age: 50-80 years * Maximum of 120 minutes of sports/outdoor activities per day * Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase * Basic smartphone skills * Sufficient knowledge of German (native language, C1 or C2) * Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer) * Consent to be informed of any additional findings Exclusion Criteria: iRBD: * Relevant cardiovascular diseases * Problems with dexterity or cognitive impairments that make it difficult to use a smartphone * Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study * Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible) Healthy controls: * Relevant cardiovascular diseases * Problems with dexterity or cognitive impairments that make it difficult to use a smartphone * Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study * Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible) * clinically diagnosed iRBD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal ganglia diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal ganglia disorder brain disorder central nervous system disorder Cognitive Dysfunction dementia multiple system atrophy nervous system disorder neurodegenerative disease Parkinson disease parkinsonian disorder Prodromal Symptoms REM sleep behavior disorder synucleinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal ganglia diseases Brain diseases Central nervous system diseases Cerebral disorder Nervous system diseases Neurodegenerative diseases Parkinson disease Parkinsonian disorders Prodromal stage Synucleinopathies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital of Bonn

    RECRUITING

    Bonn, North Rhine West-Falia, 53111, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.